Get started

Healthcare

Mednax outrageously oversold ahead of earningsIt's not every day you see a stock get this oversold on its weekly chart. Mednax, Inc. has lost about 50% of its value over the past year due to some earnings and revenue misses and year-over-year declines. After this drop, Mednax has a very attractive P/E of 8.66. Its forward P/E of 6.84 indicates that its earnings are expected to grow. S&P Capital IQ rates the company as highly undervalued. Mednax has recently had some analyst upgrades, which could serve as an upward catalyst. Also, with an ESP of 2.13% from Zacks, Mednax may beat analyst estimates when it next reports earnings on August 1. MedData's revenue has grown over the last several earnings reports, and earnings misses have been mostly due to administrative and interest payment costs. An ongoing share buyback program has reduced the number of shares of common stock, which means the company's profit will be divided by fewer shares on the next report. On the other hand, Mednax managed to miss both its own forecasts and the analysts' estimates on its last report, despite its buyback program. I don't see a lot of signs that Mednax has made progress toward cutting costs and improving margins since then. References to "restructuring" in past earnings reports are vague, but they probably refer to the so-far unsuccessful effort to sell the MedData division of the company. S&P Capital IQ rates the company as highly financially healthy, but I think that's an exaggeration. As best I can tell, the company has some pretty high-interest debt and is burning through its cash reserves. Employee reviews on Glassdoor suggest that top executives may not be providing competent leadership. These concerns aside, Mednax's undervaluation and analyst ratings make it a potentially attractive buy ahead of earnings. Even a small earnings beat could give the stock a big bump. I see some bullish divergence on the chart that suggests a slowing of its downward momentum. I'll be watching closely for signs of positive investor sentiment, with an alert set to buy at the first sign of a breakout above the parallel channel.
NYSE:MDLong
by ChristopherCarrollSmith
Under the radar buy for growth portfolioHQY Not a major headline grabber, but growth is excellent. Now the chart has opened up technically for a run to 90+ without too much static. I am accumulating here, just a few options, but holding bigger buys for a pullback/reset to 72's for a bigger load up. The Aug 16 C90 is currently sitting at .50, and premium would significantly drop on any pullback. Load the boat then, or go ahead and get feet wet now. Either way, just don't miss this ship. Once it sails it isn't coming back to port for a while. Buy and hold people should absolutely begin adding this to a long term hold growth portfolio. Happy hunting and GLTA!!
NASDAQ:HQYLong
by UnknownUnicorn1314136
EPISODE 4/11: US HEALTH CARE XLV SECTOR-TA(TREND ANALYSIS) 2019'EPISODE 4/11: US HEALTH CARE(XLV) SECTOR Technical Analysis - 16th of July 2019. There is really not much to say. Profits in the health care sector are very reliable on the cycle. Since Trump took office, the cycle extended, and hence it formed a channel as noted in the analysis. One major risk that has always affected the health care sector is regulation and political pressures . In the upcoming 2020 election, if the Democrats(pro-regulation) take office, there might be major implications to the health care sector. In any case, 50 Quarterly/200 Monthly MA(Orange line) would be the Long-term Supports , in case the current bullish channel breaks. Structural supports are marked with Purple squares. This is just a brief "free" and very detailed analysis. Perhaps in the future I might form a premium group, to whose members I will provide all the details of my research. >> I do not share my ideas for the likes or the views. This channel is only dedicated to well informed research and other noteworthy and interesting market stories .>> However, if you'd like to support me and learn more in the greatest of details , every thumbs up or follow is greatly appreciated ! -Step_Ahead_ofthemarket- Check my previous episodes on the US Sectors in the links to related ideas down below . EPISODE 3 : TECH EPISODE 2 : ENERGY * Full Disclosure: This is just an opinion, you decide what to do with your own money. For any further references- contact me.
AMEX:XLV
by step_ahead_ofthemarket
WELL Health Technologies: Strong buy below the MA200.WELL (WELL Health Technologies Corp) is one of the hottest stocks of July as it has grown so far by 77% on a monthly basis making a jump of +175% since the beginning of June. Currently this is no time to enter this frenzy as past price action has shown that after a +170% rise and overbought levels on the 1D chart, consolidation follows and then a test of the 4H MA200. Our suggestion for this asset is a strong buy once it approaches the MA200. ** If you like our free content follow our profile (www.tradingview.com) to get more daily ideas. ** Comments and likes are greatly appreciated.
WLong
by InvestingScope
United Health breakout above trendline resistanceUNH is looking like a great buy. Not only did it break out today above a downward trendline, but it's also near the bottom of an upward-sloping parallel channel. Fundamentals look good too, with generally positive analyst ratings and a series of recent earnings beats. Healthcare is hot right now, with its low China exposure and other sectors looking overbought. UNH next reports earnings in mid-July. Until then I expect a good medium-term bull run in UNH.
NYSE:UNHLong
by ChristopherCarrollSmith
1
ACASTI PHARMA INC - NASDAQ: $ACST Picking Its Head UpSince breaking-out last October'18, ACASTI PHARMA INC - NASDAQ:ACST has been trading in a side-ways grind with no real progress towards higher levels to speak of. However, we've been monitoring the action closely for some time now and it appears that ACST may just be starting to pick its head up as evidenced in the Daily chart above. With the stock trading above all of its important moving averages 20/50/200 DMA's, the technical picture remains favorable despite the lack of upside progress over the past 8-9 months. While ACST requires further work, both investors/traders may want to continue to monitor the action closely in the days/weeks ahead. In particular, should ACST be capable of clearing the $1.15 hurdle, such development may just ignite the stock and finally break free from its long slumber. Thus, both investors/traders may want to put ACST front-and-center on their radars.
A
by InsiderFinancial
ENZO BIOCHEM INC - NYSE: $ENZ FlaggingLast week, ENZO BIOCHEM INC - NYSE:ENZ broke to higher ground and in the process, recaptured its 200 DMA out of a rounding bottom and now finds itself digesting/consolidating the move within a Flag pattern on lower volume as is evidenced in the Daily chart above. In addition, ENZ is now trading above all of its important moving averages 20/50/200 DMA's and finds itself in fine technical shape. Moving forward, both investors/traders may want to continue to monitor the action with a close eye. Specifically, should ENZ be capable of going topside of the $4.50 figure, such development would likely trigger its next advance with a primary objective in the $5-$6 zone with a secondary potential objective at $7 further down the road. Nevertheless, investors/traders may want to put ENZ front-and-center on their radars.
NYSE:ENZ
by InsiderFinancial
1
Omnicell testing supportOmnicell is testing support this afternoon around the $81.50-$81.70. This has been a fairly high-volume level this week, so it should provide fairly solid support. Without catalysts in either direction, Omnicell may trade for a while in a range between the $81.50-$81.70 support level and $83.70-$84.00 resistance level. The healthcare sector as a whole appears range-bound at the moment. A downturn in technology stocks on tariff fears could be good for domestic healthcare stocks as a defensive play. Watch for that possibility next week.
NASDAQ:OMCL
by ChristopherCarrollSmith
FLEX PHARMA INC - NASDAQ: $FLKS Ready To Rumble?For the past year, FLEX PHARMA INC - NASDAQ:FLKS has found itself in base mode with the exception of a handful of sharp violent upside moves accompanied with large volume as is evidenced in the Daily chart above. In addition, we can observe that FLKS presently finds itself trading above all of its important moving averages 20/50/200 DMA's, which is technically healthy. We are watching the action very closely here as we suspect that we may very well be nearing another potential explosive move that should such development occur, we would not be the least bit surprised if the stock were to power-up into the $0.75-$1 zone in rapid fashion. Thus, both investors/traders may want to put FLKS front-and-center on their radars with a close eye on any volume pick-up that may provide clues that the stock is ready for another potential burst into northern ground.
F
by InsiderFinancial
ZIOPHARM ONCOLOGY INC. - NASDAQ: $ZIOP Building BaseAfter recapturing its 200 DMA back in March and subsequently vaulting from a 3 to 4 - handle, ZIOPHARM ONCOLOGY INC - NASDAQ:ZIOP has found itself in a sideways drift and appears to be building a base these past couple of months as we can observe from the Daily chart above. With the stock trading above all of its important moving averages 20/50/200 DMA's, ZIOP remains in a favorable technical posture as the base building process continues to develop. In addition, if one were to zoom-out to both the Weekly and Monthly time-frames, we can also see that ZIOP may just be in the process of building-out a potential inverted H&S pattern and should such development materialize and complete, the longer-term measured move implies an initial $8 objective. Moving forward, if and when at any time in the days/weeks ahead ZIOP is capable of clearing the $4.85 figure and perhaps more importantly the $5 level, such occurrence would likely suggest that higher levels are in the offing. Thus, both investors/traders may want to continue to monitor the action closely moving forward.
Z
by InsiderFinancial
R1 RCM INC - NASDAQ: $RCM Blue Sky's Await?After breaking to higher ground last month, shares of R1 RCM INC - NASDAQ:RCM have been digesting/consolidating the move in orderly fashion and now finds itself pressing the upper level and nearing a potential break for all-time highs as well as Blue Sky's as evidenced in the Daily chart above. In addition, RCM presently trades above all of its important moving averages 20/50/200 DMA's, which portrays a healthy technical picture and posture. Furthermore, the stock has been putting-in higher lows; higher highs throughout the 2019 calendar validating its uptrend. Moving forward, should RCM be capable of going topside of the 12.50 figure and can hold and or sustain, it's all-time high and Blue Sky territory. Thus, both investors/traders may want to continue to monitor the action closely in the days ahead for signs/clues that RCM has loftier levels in sight.
R
by InsiderFinancial
AMARIN CORP - NASDAQ: $AMRN Setting-UpAfter breaking to higher ground in 1Q19 and subsequently drifting back down to its original break-out level in the upper teen's, the shares of AMARIN CORP NASDAQ: AMRN are once again starting to show signs of potentially setting-up for another attempt at loftier levels as evidenced in the Daily chart above. While AMRN presently finds itself in drift mode working on its right-side, the stock continues to display favorable technical characteristics trading above all of its important moving averages (20/50/200 DMA's). Although further work is required, it appears that we may just witness a repeat of 1Q whereby buyers once again start to take control of the stock and should such scenario materialize, we suspect that it may have eyes for the $22 - $24 zone once again in the short-term. Thus, both investors/traders may want to continue to monitor the action closely in the days/weeks ahead for signs/clues that a move for greener pastures is underway.
NASDAQ:AMRN
by InsiderFinancial
$JSENTC Netcare 911, we have an emergency!This chart looks like an emergency that requires an urgent intervention! Perhaps the major volume seen today could be an indication of capitulation and i will be monitoring the price action in the days ahead to see if it is able to recover from these over extended levels. Should this level hold which is also coincidentally the bottom of the downward sloping channel, we could see a bounce take place to the R21.00 - R21.60 area. R21.60 is an area where the chart also has a small gap which might want to fill first before any further downside ensues.
JSE:NTCLong
by MarcoOlevano
Long GWPHUrg.. tradingview decided to hide a lot of my previous idea because I didn't go pro, what a scam. If you like my charts and would like to support me going pro for $12.95, please msg me so i can keep sending out these ideas weekly. TradingView Open position at $182 Stop loss at $180 Take profit at $187 Why this play? Gwph had a pretty good earning but got beaten down due to market conditions. they had a lot of upgrades with price range of $200+ the last few days but they can't move with market uncertainty. AS soon as market runs, they will fly, but ofc that will depend on market.
GLong
by WallSt007